(喹唑啉-4-氨基)-乙酸 | 55040-11-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: (喹唑啉-4-氨基)-乙酸
• 英文名称: N-quinazolin-4-yl-glycine
• 英文别名: 2-(Quinazolin-4-ylazaniumyl)acetate
• CAS: 55040-11-4
• 化学式: C₁₀H₉N₃O₂
• mdl: MFCD02046507
• 分子量: 203.2
• InChiKey: GQLYDNMTAYXPLC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  75.1
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  5-硝基糠醛 、 (喹唑啉-4-氨基)-乙酸 在 sodium acetate 作用下， 以 溶剂黄146 为溶剂， 生成 3-(5-nitro-furan-2-ylmethylene)-imidazo[1,2-c]quinazolin-2-one
  参考文献：
  名称：

  Cyclization of N-(4-quinazolyl)-?-amino carboxylic acids

  摘要：

  DOI：

  10.1007/bf00480406

文献信息

• IDO Inhibitors
  申请人：NewLink Genetics Corporation

  公开号：US20130289083A1

  公开（公告）日：2013-10-31

  Presently provided are methods for (a) modulating an activity of indoleamine 2,3-dioxygenase comprising contacting an indoleamine 2,3-dioxygenase with a modulation effective amount of a compound as described in one of the aspects described herein; (b) treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression in a subject in need thereof, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (c) treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (d) enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent and a compound as described in one of the aspects described herein; (e) treating tumor-specific immunosuppression associated with cancer comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; and (f) treating immunsupression associated with an infectious disease, e.g., HIV-1 infection, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount a compound as described in one of the aspects described herein.

  目前提供的方法包括：(a) 通过将一种如本文所述的化合物的调节有效量与吲哚胺2,3-双加氧酶接触来调节其活性；(b) 治疗需要抑制吲哚胺2,3-双加氧酶(IDO)介导的免疫抑制的患者，包括给予如本文所述的化合物的有效抑制吲哚胺2,3-双加氧酶的量；(c) 治疗需要抑制吲哚胺2,3-双加氧酶酶活性的医疗状况，包括给予如本文所述的化合物的有效抑制吲哚胺2,3-双加氧酶的量；(d) 增强抗癌治疗的有效性，包括给予抗癌药物和如本文所述的化合物；(e) 治疗与癌症相关的肿瘤特异性免疫抑制，包括给予如本文所述的化合物的有效抑制吲哚胺2,3-双加氧酶的量；(f) 治疗与传染病相关的免疫抑制，例如HIV-1感染，包括给予如本文所述的化合物的有效抑制吲哚胺2,3-双加氧酶的量。
• Cyclization of N-(4-quinazolyl)-?-amino carboxylic acids
  作者：I. V. Mazur、R. S. Sinyak、R. I. Katkevich、P. M. Kochergin

  DOI：10.1007/bf00480406

  日期：1976.9